Buy
Sell
Share Name Share Symbol Market Type Share ISIN Share Description
Amryt Pharma Plc LSE:AMYT London Ordinary Share GB00BKLTQ412 ORD 6P
  Price Change % Change Share Price Bid Price Offer Price High Price Low Price Open Price Shares Traded Last Trade
  0.00 0.0% 167.50 165.00 170.00 167.50 167.50 167.50 3,400 08:00:00
Industry Sector Turnover (m) Profit (m) EPS - Basic PE Ratio Market Cap (m)
Pharmaceuticals & Biotechnology 49.2 -56.5 -72.8 - 300

Amryt Pharma Share Discussion Threads

Showing 4276 to 4298 of 6725 messages
Chat Pages: Latest  173  172  171  170  169  168  167  166  165  164  163  162  Older
DateSubjectAuthorDiscuss
27/1/2019
19:02
My comment was about potential regional outlicensing deal for Episalvan (eg North America or Asia Pacific markets) whereby upfront payment is made to Amryt. Rather than another inlicensing deal, like Lojuxta. It’s only a few weeks since EASE interims were released and it will take a while for other companies to understand and evaluate the interim results, discuss with Amryt and strike a potential deal. It has been my hope that Amryt could strike a licensing deal with a company like Amicus, eg to take on North America distribution of Episalvan.
diamondstar1
27/1/2019
18:29
You could be correct, bioking. The largest shareholder is Software AG with over 20%. They increased their %age stake at the last placing. I very much doubt if Cathal Friel will be taking part in any future placing!! He didn't take part in the last one and last May sold around a third of his shares @ 17p. With the benefit of hindsight he got that right. Someone buying into AP101 (such as Amicus) is AMYT's best chance of avoiding a placing, IMO. PS. Re diamondstar's comment about another licensing deal, I can't see that AMYT have the cash available to make an upfront payment to secure another Lojuxta type licensing deal. They were lucky with Lojuxta as they didn't have to pay an upfront fee to Aegerion. Aegerion was in a very bad way at the time due to previous miss-selling of Lojuxta in the USA. They were pulling out of all their markets at the time with the exception of the America's and Japan because of their need to conserve cash and reduce expenditure in order to survive. Any kind of deal that gave them future royalty payments was to be welcomed, even if there was no upfront payment involved. Beggars can't be choosers.
papillon
27/1/2019
17:08
positive is that the two founders (wiley & Nealon) of AMYT owns more than 30 million shares together so maybe they will try to avoid dilution to protect their investment.
bioking
27/1/2019
14:09
How AMYT go about raising the cash they need (probably in H1 2019) will impact the share price A placing would likely mean a lower sp, whilst a loan, or better still an Amicus/Socioderm type licensing deal for AP101 would likely mean a significantly higher share price (in the case of a AP101 licensing deal). You pays your money, you takes your choice. I've hedged my bets by selling some of my AMYT shares, but I'm keeping the rest because I'm hopeful that AMYT will raise their cash without having to go down the placing route. Fingers crossed as always!! EDIT: I'm 90% confident that the EASE trial will prove to be successful when the final results RNS is issued in H2 2019 so I'm 90% confident that the AMYT share price will be significantly higher than the current 16.25p at the end of 2019. However I have no confidence on whether the share price will go higher, or lower, than the current 16.25p in what remains of H1 2019. Hence why I de-risked by selling around half of my shares recently.
papillon
27/1/2019
13:01
bioking is correct about AMYT needing a further cash injection and very soon. That's the main reason why I have halved my holding in the past few weeks after the RNS's dated the 4th & 7th January failed to achieve lift off and to get anywhere near the 24p warrant exercise price. I think the BoD thought that the interim EASE news would be good enough to enable them to receive the £5m following exercise of the warrants which is why they extended the warrant expiry date from 31/12/2018 to 11/1/2019. Cash is King, especially for AIM listed companies with no revenue stream, or in AMYT's case a revenue stream that doesn't go anywhere near to making enough profit to cover their cash burn. I don't know which route AMYT will go down to raise cash, but another placing must be a distinct possibility. If so what would be the placing price? I wish I was a knowledgeable "insider" instead of an ignorant "outsider"! LOL.
papillon
27/1/2019
10:58
standard approval process takes exact 12 months you must add 2 months of NDA review to the 10 months drug review . But that doesnt care the main issue is still the very low cash balance which they must resolve in the coming weeks and most potential investors like me will wait because if there is a massive share offering then stock will drop hard . Maybe i will send an email to IR asking what they will do about that cash issue .
bioking
27/1/2019
09:31
Yes, BK, the Priority Voucher, as a concept originally came from David Ridley of Duke, and the idea was that Pharma companies would get awarded the voucher once their original drug was approved, and this could then be used for faster approval of their next drug. So you are right in that the prerequisite for being able to sell the voucher is to get Episalvan approved by FDA first. With regards to timelines, I believe that Amryt will be pushing for faster approval timelines. I believe they will begin preparing for the filing for FDA and EMA earlier with exisiting data, and on the assumption that full EASE is positive ie At Risk. Hence, when the EASE finals arrives in Q4 2019, all they will need to do is complete the dossier with the final results. For this reason, I believe Q1 2020 FDA filing is possible, and with standard 10 month timelines, FDA approval in end 2020 (rather than end 2021) is also possible. With regards to share price over the next 1-2 years, I agree that there could be downward pressure and movement. However, this assumes that Amryt do not have any positive news flow over this timeframe. If Amryt announces a licensing agreement with another company such as Amicus, share price could as easily go above 20p (as it also could go to 10p without any positive news, as you have suggested).
diamondstar1
27/1/2019
07:33
AMYT will NOT get the priority voucher until the Drug gets FDA approval maybe by end 2021 IF phase 3 outcome is positiv .They running out of Cash in March the only 2 options they have to avoid massive dilution is Debt financing or selling the commercial rights of AP101 . I like the company but will wait untill the cash issue gets resolved i think it will drop back to 10p or even lower .They need minimum €30 million just to survive the next 2 years ,lojuxta sales are still low and will need around 2-3 years to help the co to reach break-even IF burn-rate stays at current level . "The US Congress created the priority review voucher program in 2007 based on a 2006 Health Affairs paper (Ridley et al. 2006). Under the law, following approval by the Food and Drug Administration (FDA) of a treatment for a neglected or rare pediatric disease, the developer receives a voucher for priority review for a different drug. Two drugs receive priority review for each voucher: the drug winning a voucher for a neglected or rare pediatric disease, and the drug using a voucher for another indication."
bioking
26/1/2019
23:44
Yes it's true what you say about the FDA priority voucher, diamondstar, so the potential EUR10m payment to Birken pales into insignificance. I'd forgotten about that priority voucher. However the AMYT share price could stay weak in the short term if investors perceive a placing is imminent. The £5m from the 24p warrants being exercised could have been a short term saviour for AMYT.
papillon
26/1/2019
22:45
Thanks, that’s what I was thinking. That’s surely a ‘wow’ isn’t it?! I guess our share price reflects that we are little known and perhaps even less understood. This could be an absolute cracker! Thanks again Baz
bazworth
26/1/2019
22:45
Thanks, that’s what I was thinking. That’s surely a ‘wow’ isn’t it?! I guess our share price reflects that we are little known and perhaps even less understood. This could be an absolute cracker! Thanks again Baz
bazworth
26/1/2019
22:22
Hi Baz, If EASE full results are positive (as I personally expect it to be), then Amryt will file their drug dossier with the FDA. They will have 2 options at this stage 1) Use the FDA Priority Voucher themselves, which will reduce FDA review time from 10 to 6 months or 2) Sell off the voucher for 70-150 million USD and go with ‘standard̵7; FDA review times. Without doubt, Amryt will choose the latter option, as I believe they are realistic enough & understand that Episalvan is not a ‘blockbuster’ category drug (ie achieving annual sales of at least USD 1 billion annually) and saving 4 months off review period will not make that much difference for the launch of Episalvan for EB. So, to answer your question, I would say, yes, the priority voucher which they already have been awarded, is theirs to sell if they achieve positive EASE results.
diamondstar1
26/1/2019
21:52
diamondstar1, Please elaborate, so if we see through the final hurdles of EASE, then we pretty much are certain of having a sellable asset worth USD70 to 150 million? I once read that you shouldn’t invest in something that you don’t understand, I’m well over the top here......! Thanks in advance Baz
bazworth
26/1/2019
21:36
Hi Paps, I agree with what you are saying about cash burn, and your question whether increase in Lojuxta revenue can offset this. However, with regards to the Euro 10,000,000 due to Birken, this is subject to firstly positive EASE final results & approval of Episalvan for EB by the FDA or EMA. The earliest they will submit their dossier for Marketing Authorisation approval is around Q1 2020, and the earliest they can achieve marketing approval is Q1 2021. Hence, this milestone payment is far away. Assuming positive EASE, we should hear news of the sale of the priority voucher first, worth USD70-150 million. This will overshadow the Birken payment.
diamondstar1
26/1/2019
17:46
I wonder what the current cash position is at AMYT? They did receive a EUR8.4m funding grant from the Irish Govt, but that's over 3 years and is solely for the development of AP103. It doesn't cover the AP101 trial expenses and AMYT admin. AMYT had EUR12.2m of cash at 30th June 2018. The second tranche, of the EIB loan, of EUR5m was drawn down in September 2018. AMYT "burnt" EUR8.3m during H1 2018 (EUR20.5m @ 31/1/2017 - EUR12.2m). Assuming the same rate of cash "burn" in H2 2018 that would have left AMYT with EUR3.9m (EUR12.2m - EUR8.3m) + EUR5m (2nd tranche of EIB loan) = EUR8.9m at 31st December 2018. Assuming a similar cash "burn" as in H1 2018 that would leave AMYT with just EUR0.6m of cash remaining at 30th June 2019. On the basis of my analysis we are due another placing sometime in H1 2019. Of course I have made the assumption that the cash "burn" in H2 2018 and H1 2019 is the same as the reported cash "burn" in H1 2018. Will that be the case? Unfortunately in the absence of the cash "burn" figure in H2 2018 my analysis is the best I can come up with. The actual cash "burn" figure for H2 2018 could be higher, or lower, than my EUR8.3m. Similarly my projected cash "burn" figure of EUR8.3m for H1 2019 could be higher, or lower. However I'm pretty certain that we will get another placing sometime during 2019. Only much higher Lojuxta revenue could postpone that placing, but I doubt Lojuxta revenue will be high enough. PS. AMYT have a fair chunk of cash to pay the vendors of Birken. This is what the interim report dated 26/9/2018 states: "EUR10,000,000 on receipt of marketing approval by the EMA or FDA of a pharmaceutical product containing Betulin as its API for the treatment of Epidermolysis Bullosa (EB);" AMYT also have the EIB loan to repay 5 years after first drawdown. Currently they have drawn down EUR15m of that loan. That loan will need to be repaid in H1 2022.
papillon
25/1/2019
12:25
Did have 39k of these a few weeks ago. Now have just 20k. Made a small profit because of the shares I bought sub 16p in Oct, Nov & Dec. Will I keep this 20k? I don't know. The share price is going sideways. It seems poised for a big percentage RISE, or FALL, on the next significant news. Hopefully the former!
papillon
24/1/2019
13:34
Well the Final Results RNS was issued on the 17th of April last year. Let's hope we don't have to wait until the middle of April this year for the next news. Also when we do get news lets hope it's good news and NOT bad news (such as another placing!).
papillon
16/1/2019
17:45
I bought those extra 14,000+ shares, bazworth, in anticipation that the release of the EASE interim analysis would lead to a big spike up in the AMYT share price Unfortunately it never happened.
papillon
16/1/2019
17:26
Happy to keep my chunk locked away....!
bazworth
16/1/2019
17:03
Early last week I had just over 39,000 shares. I started selling last week and sold another 5,000 today just before the close. Now have 25,000 shares left. Gone back to my core holding. Probably keep them. Made a little bit of profit because that 14,000+ shares was bought in October, November & December at below 16p.
papillon
15/1/2019
21:55
AMYT log chart. free stock charts from uk.advfn.com
papillon
15/1/2019
21:22
biopharmas can damage your wealth. NSCI proves that. The NCSI share price has dropped from 72p to today's 3.35p (down 51.54% on the day) in exactly 12 months on bad newsflow. Neil Woodford's investment management has been a big loser (or rather his investors have!). NSCI's Chairman is Sir Richard Sykes a former big hitter in the pharma industry (Glaxo Wellcome & GlaxoSmithKline). Rather like AMYT's chairman, Harry Stratford, in fact. Where's the short term bottom for AMYT? Unfortunately the losses PI's have suffered at FARN, IMM, NSCI, etc hasn't helped the AMYT share price
papillon
15/1/2019
11:56
Fair play to mdalos. He tipped INFA before Christmas. It's more than doubled since he mentioned it!
papillon
Chat Pages: Latest  173  172  171  170  169  168  167  166  165  164  163  162  Older
ADVFN Advertorial
Your Recent History
LSE
AMYT
Amryt Phar..
Register now to watch these stocks streaming on the ADVFN Monitor.

Monitor lets you view up to 110 of your favourite stocks at once and is completely free to use.

By accessing the services available at ADVFN you are agreeing to be bound by ADVFN's Terms & Conditions

P: V: D:20210723 20:11:46